An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803
收藏DataCite Commons2025-01-06 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002839/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have completed natalizumab Studies C-1801, C-1802, or C-1803.
提供机构：
Vivli
创建时间：
2018-10-27
